Kagami A, Hino K, Mochizuki K, Sakamoto T, Tada N, Ishikawa T, Manabe M, Satoh N
Department of Internal Medicine, Aoto Hospital, Jikei University School of Medicine.
Nihon Ronen Igakkai Zasshi. 1991 Nov;28(6):748-54. doi: 10.3143/geriatrics.28.748.
An assessment has been made regarding the changes of the particles of lipoprotein A-I without A-II (Lp A-I) and lipoprotein A-I with A-II (LpA-I/A-II) which correspond to HDL subfraction isolated by the use of anti-apo A-I and A-II antibody affinity columns in order to quantitatively and qualitatively investigate the change of HDL caused by administration of probucol and pravastatin which are therapeutic drugs for hypercholesterolemia. Probucol caused significant decreases of HDL-cholesterol, plasma apo A-I/apo A-II ratio and particles larger in diameter than 10.4 nm. Comparing Lp A-I and A-I/A-II ratios with those in normolipidemic controls and the ratios before and after administration of probucol, the decrease of LpA-I ratio was found to be remarkable after prolonged administration of probucol, and it was presumed that the decrease of HDL cholesterol by prolonged administration reflects the decrease of LpA-I particles more than the decrease of LpA-I/A-II. On the other hand, no significant change was seen in HDL cholesterol, plasma apo A-I/apo A-II ratio or HDL particle size in the pravastatin group. It is considered essential to observe HDL from the aspect of apoprotein, which plays an important role in the metabolism of lipoprotein, in the assessment of the anti-atherogenic activity of HDL cholesterol in future. In other words, it is necessary to analyze the change of HDL from the aspect of Lp A-I and Lp A-I/AII and investigate their respective metabolisms and roles.
为了定量和定性地研究用于治疗高胆固醇血症的药物普罗布考和普伐他汀给药后引起的高密度脂蛋白（HDL）变化，对不含载脂蛋白A-II（A-II）的载脂蛋白A-I（Lp A-I）颗粒和含A-II的载脂蛋白A-I（LpA-I/A-II）颗粒的变化进行了评估，这些颗粒对应于通过使用抗载脂蛋白A-I和A-II抗体亲和柱分离的HDL亚组分。普罗布考导致HDL胆固醇、血浆载脂蛋白A-I/载脂蛋白A-II比值以及直径大于10.4 nm的颗粒显著减少。将Lp A-I和A-I/A-II比值与正常血脂对照组以及普罗布考给药前后的比值进行比较，发现长期服用普罗布考后LpA-I比值的下降尤为显著，并且推测长期给药导致的HDL胆固醇下降更多地反映了LpA-I颗粒的减少而非LpA-I/A-II的减少。另一方面，普伐他汀组的HDL胆固醇、血浆载脂蛋白A-I/载脂蛋白A-II比值或HDL颗粒大小均未出现显著变化。在未来评估HDL胆固醇的抗动脉粥样硬化活性时，从在脂蛋白代谢中起重要作用的载脂蛋白方面观察HDL被认为是至关重要的。换句话说，有必要从Lp A-I和Lp A-I/AII方面分析HDL的变化，并研究它们各自的代谢和作用。
